Oct 25, 2019 - During ACADIA's (ACAD) third-quarter 2019 conference call, investor focus will be on the sales figure of its only marketed drug Nuplazid and its label expansion studies.
Oct 25, 2019 - During Vertex's (VRTX) third-quarter earnings call, investor focus will be on the uptake of its newest CF drug Symdeko and the update on the recent approval of Trikafta triple combination regimen.
Oct 24, 2019 - BioMarin (BMRN) rides high on earnings and revenue beat in the third quarter of 2019.
Oct 24, 2019 - During Acorda's (ACOR) third-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.
Oct 24, 2019 - Investors are looking forward to Revlimid's performance and updates on the acquisition by Bristol-Myers, when Celgene Corporation (CELG) reports Q3 results.
Oct 23, 2019 - Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales growth in the third quarter.
Oct 23, 2019 - Investments in new geographies and customer experience are likely to have aided T-Mobile's (TMUS) third-quarter 2019 financial and operating results.
Oct 22, 2019 - Sarepta Therapeutics' (SRPT) third-quarter results are expected to reflect the impact of strong demand for Exondys 51. Regulatory update related to golodirsen is what investors are expected be focused on.
Oct 21, 2019 - AstraZeneca's (AZN) third-quarter result is expected to reflect the impact of new drug sales.
Oct 18, 2019 - Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.